Haemophilia A and B are hereditary haemorrhagic disorders characterised by deficiency or
dysfunction of coagulation protein factors VIII and IX, respectively. Recurrent joint and …

Although significant advances in hemophilia treatment have improved patient outcomes and
quality of life, one of the greatest complications in severe hemophilia A is the development of …

Background The development of neutralizing anti–factor VIII alloantibodies (inhibitors) in
patients with severe hemophilia A may depend on the concentrate used for replacement …

Emicizumab, a bispecific humanized monoclonal antibody, bridges activated factor IX (FIX)
and FX to restore the function of missing activated FVIII in hemophilia A. Emicizumab …

Introduction As a result of the new treatment paradigm that the haemophilia community will
face with the availability of novel (non‐factor) therapies, an updated consensus on ITI …

Introduction Emicizumab is a bispecific monoclonal antibody that mimics factor VIII (FVIII) by
binding to factors IXa and X to promote hemostasis in haemophilia A (HA) and HA with …

Against a background of a rapidly evolving treatment landscape, a contemporary, evidence‐
based consolidated understanding of mortality in people with congenital hemophilia A …

Hemophilia A (HA) is an X-linked hereditary bleeding disorder caused by deficiency of
coagulation factor (F) VIII activity. One of the greatest complications in the treatment of HA is …

The availability of longitudinal data collected prospectively from 1998 to 2011 at federally
funded US hemophilia treatment centers provided an opportunity to construct a descriptive …

Subcutaneous emicizumab enables prophylaxis for people with hemophilia A (HA) from
birth, potentially reducing risk of bleeding and intracranial hemorrhage (ICH). HAVEN 7 …